196 related articles for article (PubMed ID: 38575601)
1. Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy.
Parmasad JA; Ricke KM; Nguyen B; Stykel MG; Buchner-Duby B; Bruce A; Geertsma HM; Lian E; Lengacher NA; Callaghan SM; Joselin A; Tomlinson JJ; Schlossmacher MG; Stanford WL; Ma J; Brundin P; Ryan SD; Rousseaux MWC
Cell Death Dis; 2024 Apr; 15(4):246. PubMed ID: 38575601
[TBL] [Abstract][Full Text] [Related]
2. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
3. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
[TBL] [Abstract][Full Text] [Related]
4. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
5. Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy.
Chatterjee D; Sanchez DS; Quansah E; Rey NL; George S; Becker K; Madaj Z; Steiner JA; Ma J; Escobar Galvis ML; Kordower JH; Brundin P
J Parkinsons Dis; 2019; 9(2):315-326. PubMed ID: 30932894
[TBL] [Abstract][Full Text] [Related]
6. GV-971 attenuates α-Synuclein aggregation and related pathology.
Yu Z; Yang Y; Chan RB; Shi M; Stewart T; Huang Y; Liu Z; Lan G; Sheng L; Tian C; Yang D; Zhang J
CNS Neurosci Ther; 2024 Feb; 30(2):e14393. PubMed ID: 37563872
[TBL] [Abstract][Full Text] [Related]
7. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
[TBL] [Abstract][Full Text] [Related]
8. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
[TBL] [Abstract][Full Text] [Related]
9. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
10. Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein.
Howe JW; Sortwell CE; Duffy MF; Kemp CJ; Russell CP; Kubik M; Patel P; Luk KC; El-Agnaf OMA; Patterson JR
Parkinsonism Relat Disord; 2021 Aug; 89():41-47. PubMed ID: 34218047
[TBL] [Abstract][Full Text] [Related]
11. Alpha-Synuclein Preformed Fibrils Induce Cellular Senescence in Parkinson's Disease Models.
Verma DK; Seo BA; Ghosh A; Ma SX; Hernandez-Quijada K; Andersen JK; Ko HS; Kim YH
Cells; 2021 Jul; 10(7):. PubMed ID: 34359864
[TBL] [Abstract][Full Text] [Related]
12. Neuroinflammatory gene expression profiles of reactive glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions.
Stoll AC; Kemp CJ; Patterson JR; Howe JW; Steece-Collier K; Luk KC; Sortwell CE; Benskey MJ
Neurobiol Dis; 2024 Feb; 191():106411. PubMed ID: 38228253
[TBL] [Abstract][Full Text] [Related]
13. Striatal Afferent BDNF Is Disrupted by Synucleinopathy and Partially Restored by STN DBS.
Miller KM; Patterson JR; Kochmanski J; Kemp CJ; Stoll AC; Onyekpe CU; Cole-Strauss A; Steece-Collier K; Howe JW; Luk KC; Sortwell CE
J Neurosci; 2021 Mar; 41(9):2039-2052. PubMed ID: 33472823
[TBL] [Abstract][Full Text] [Related]
14. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3.
Mao X; Ou MT; Karuppagounder SS; Kam TI; Yin X; Xiong Y; Ge P; Umanah GE; Brahmachari S; Shin JH; Kang HC; Zhang J; Xu J; Chen R; Park H; Andrabi SA; Kang SU; Gonçalves RA; Liang Y; Zhang S; Qi C; Lam S; Keiler JA; Tyson J; Kim D; Panicker N; Yun SP; Workman CJ; Vignali DA; Dawson VL; Ko HS; Dawson TM
Science; 2016 Sep; 353(6307):. PubMed ID: 27708076
[TBL] [Abstract][Full Text] [Related]
15. PTEN-Induced Putative Kinase 1 Dysfunction Accelerates Synucleinopathy.
Nguyen TT; Kim YJ; Lai TT; Nguyen PT; Koh YH; Nguyen LTN; Ma HI; Kim YE
J Parkinsons Dis; 2022; 12(4):1201-1217. PubMed ID: 35253778
[TBL] [Abstract][Full Text] [Related]
16. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
Gegg ME; Verona G; Schapira AHV
Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
[TBL] [Abstract][Full Text] [Related]
17. Amelioration of pathologic α-synuclein-induced Parkinson's disease by irisin.
Kam TI; Park H; Chou SC; Van Vranken JG; Mittenbühler MJ; Kim H; A M; Choi YR; Biswas D; Wang J; Shin Y; Loder A; Karuppagounder SS; Wrann CD; Dawson VL; Spiegelman BM; Dawson TM
Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2204835119. PubMed ID: 36044549
[TBL] [Abstract][Full Text] [Related]
18. A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons.
Luo J; Sun L; Lin X; Liu G; Yu J; Parisiadou L; Xie C; Ding J; Cai H
Hum Mol Genet; 2014 Dec; 23(24):6567-74. PubMed ID: 25051958
[TBL] [Abstract][Full Text] [Related]
19. Anti-α-synuclein c-terminal antibodies block PFF uptake and accumulation of phospho-synuclein in preclinical models of Parkinson's disease.
Brendza R; Gao X; Stark KL; Lin H; Lee SH; Hu C; Cai H; DiCara D; Hsiao YC; Ngu H; Foreman O; Baca M; Dohse M; Fortin JP; Corpuz R; Seshasayee D; Easton A; Ayalon G; Hötzel I; Chih B
Neurobiol Dis; 2023 Feb; 177():105969. PubMed ID: 36535551
[TBL] [Abstract][Full Text] [Related]
20. Modeling α-Synucleinopathy in Organotypic Brain Slice Culture with Preformed α-Synuclein Amyloid Fibrils.
Roux A; Wang X; Becker K; Ma J
J Parkinsons Dis; 2020; 10(4):1397-1410. PubMed ID: 32716318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]